Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04815720 · ClinicalTrials.gov registry record · Phase 1
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
A Phase 1 study of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), sponsored by Vaccinex.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
- 15
- Study locations
NCT04815720 is a Phase 1 study of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) that has completed, run by Vaccinex. The registered enrollment target is 49 participants. The trial reports 15 study locations across 12 states.
The verdict
NCT04815720, a Phase 1 study of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), has completed, sponsored by Vaccinex.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of the study is to evaluate the safety and tolerability of pepinemab in combination with pembrolizumab as first-line treatment and determine a recommended Phase 2 dose (RP2D) in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Conditions Studied
Interventions
- DRUG pepinemab + pembrolizumab
Study Locations (15)
California
- California Cancer Associates for Research and Excellence (CCARE)-Fresno - Fresno
- UCSF Medical Center at Mission Bay - San Francisco
Florida
- AdventHealth Celebration - Celebration
- AdventHealth Orlando - Orlando
New York
- Northwell Health - Centers for Advanced Medicine - Lake Success
- University of Rochester - Rochester
Arkansas
- Highlands Oncology Group, PA - North Hills - Springdale
Connecticut
- Yale Cancer Center - New Haven
Georgia
- Emory Saint Joseph's Hospital - Atlanta
Maryland
- American Oncology Partners of Maryland, PA - Bethesda
Missouri
- Siteman Cancer Center - Washington University Medical Campus - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2021-08-09 |
| Est. Completion | 2024-07-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04815720
The ClinicalTrials.gov registry entry for NCT04815720 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vaccinex, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) appearing as the primary indexed condition, and to 1 intervention - of which pepinemab + pembrolizumab is the first listed.
NCT04815720 reports 15 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT04815720 about?
NCT04815720 is a clinical study titled "Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck". The purpose of the study is to evaluate the safety and tolerability of pepinemab in combination with pembrolizumab as first-line treatment and determine a recommended Phase 2 dose (RP2D) in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
What is the current status of trial NCT04815720?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2021-08-09. Estimated completion is 2024-07-24.
What conditions does trial NCT04815720 study?
This clinical trial studies the following conditions: Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC).
What interventions are being tested in trial NCT04815720?
The interventions under investigation include: pepinemab + pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT04815720?
This trial is sponsored by Vaccinex, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04815720 being conducted?
This trial has 15 study locations across Arkansas, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.